Optimistic Buy Rating for Acurx Pharmaceuticals Driven by Promising Developments and Financial Strength
I'm PortAI, I can summarize articles.
Acurx Pharmaceuticals received a Buy rating from analyst Matthew Keller of H.C. Wainwright, with a price target of $31.00. This positive outlook is driven by significant developments in the company's lead compound, ibezapolstat (IBZ), including increased visibility through publications and presentations. Acurx is also exploring financing opportunities to expedite IBZ's development, supported by a recent warrant exercise that boosted cash reserves. Preclinical data presented at IDWeek ’25 showcased IBZ's unique properties, enhancing its potential in treating challenging bacterial infections.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments